Stuart J Knechtle

List of Publications by Year
in descending order

311 papers	16,669 citations	14655 66 h-index	19749 117 g-index
463 all docs	463 docs citations	463 times ranked	10973 citing authors

#	Article	IF	Citations
1	RISK FACTORS FOR PRIMARY DYSFUNCTION AFTER LIVER TRANSPLANTATIONâ€"A MULTIVARIATE ANALYSIS. Transplantation, 1993, 55, 807-813.	1.0	937
2	CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection inâ€‰primates. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 8789-8794.	7.1	905
3	Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nature Medicine, 1999, 5, 686-693.	30.7	801
4	2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. American Journal of Transplantation, 2016, 16, 2816-2835.	4.7	451
5	Campath-1H Induction Plus Rapamycin Monotherapy for Renal Transplantation: Results of a Pilot Study. American Journal of Transplantation, 2003, 3, 722-730.	4.7	360
6	THE PREDICTIVE VALUE OF DONOR LIVER BIOPSIES FOR THE DEVELOPMENT OF PRIMARY NONFUNCTION AFTER ORTHOTOPIC LIVER TRANSPLANTATION. Transplantation, 1991, 51, 157-163.	1.0	346
7	Donation After Cardiac Death. Annals of Surgery, 2005, 242, 724-731.	4.2	342
8	Urinary-Cell mRNA Profile and Acute Cellular Rejection in Kidney Allografts. New England Journal of Medicine, 2013, 369, 20-31.	27.0	312
9	Experience With 500 Simultaneous Pancreas-Kidney Transplants. Annals of Surgery, 1998, 228, 284-296.	4.2	275
10	RESULTS OF THE DOUBLE-BLIND, RANDOMIZED, MULTICENTER, PHASE III CLINICAL TRIAL OF THYMOGLOBULIN VERSUS ATGAM IN THE TREATMENT OF ACUTE GRAFT REJECTION EPISODES AFTER RENAL TRANSPLANTATION1,2. Transplantation, 1998, 66, 29-37.	1.0	273
11	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
12	Pneumatosis Intestinalis. Annals of Surgery, 1990, 212, 160-165.	4.2	205
13	Sensitization in Transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. American Journal of Transplantation, 2018, 18, 1604-1614.	4.7	205
14	FN18-CRM9 IMMUNOTOXIN PROMOTES TOLERANCE IN PRIMATE RENAL ALLOGRAFTS1. Transplantation, 1997, 63, 1-6.	1.0	196
15	Dissociation of Depletional Induction and Posttransplant Lymphoproliferative Disease in Kidney Recipients Treated With Alemtuzumab. American Journal of Transplantation, 2007, 7, 2619-2625.	4.7	194
16	SUCCESSFUL EXTRARENAL TRANSPLANTATION FROM NON-HEART-BEATING DONORS. Transplantation, 1995, 59, 977-982.	1.0	190
17	Expression of Naked Plasmid DNA Injected into the Afferent and Efferent Vessels of Rodent and Dog Livers. Human Gene Therapy, 1997, 8, 1763-1772.	2.7	186
18	Î±1-Adrenergic effects and liver regeneration. Hepatology, 1987, 7, 1189-1194.	7.3	184

#	Article	IF	Citations
19	The Role of Donor-Specific HLA Alloantibodies in Liver Transplantation. American Journal of Transplantation, 2014, 14, 779-787.	4.7	182
20	Liver transplantation from controlled non-heartâ€“beating donors. Surgery, 2000, 128, 579-588.	1.9	177
21	Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation, 2020, 104, 911-922.	1.0	172
22	CD4+CD25+FOXP3+ Regulatory T Cells Increase De Novo in Kidney Transplant Patients After Immunodepletion with Campath-1H. American Journal of Transplantation, 2008, 8, 793-802.	4.7	158
23	Costimulation Blockade Alters Germinal Center Responses and Prevents Antibody-Mediated Rejection. American Journal of Transplantation, 2014, 14, 59-69.	4.7	157
24	Elevation of CXCR3-Binding Chemokines in Urine Indicates Acute Renal-Allograft Dysfunction. American Journal of Transplantation, 2004, 4, 432-437.	4.7	156
25	DETERMINANTS OF GRAFT SURVIVAL AFTER RENAL TRANSPLANTATION1. Transplantation, 1996, 61, 1581-1586.	1.0	153
26	Donation After Cardiac Death: The University of Wisconsin Experience with Renal Transplantation. American Journal of Transplantation, 2004, 4, 1490-1494.	4.7	152
27	Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery, 2004, 136, 754-760.	1.9	139
28	A New Look at Blockade of T-cell Costimulation: A Therapeutic Strategy for Long-term Maintenance Immunosuppression. American Journal of Transplantation, 2006, 6, 876-883.	4.7	135
29	The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant International, 2006, 19, 705-714.	1.6	131
30	Simultaneous Pancreas-Kidney Transplantation and Living Related Donor Renal Transplantation in Patients With Diabetes: Is There a Difference in Survival?. Annals of Surgery, 2000, 231, 417-423.	4.2	122
31	STUDIES OF PEDIATRIC LIVER TRANSPLANTATION (SPLIT): YEAR 2000 OUTCOMES. Transplantation, 2001, 72, 463-476.	1.0	119
32	LONG-TERM RESULTS OF LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER12. Transplantation, 2000, 70, 780-783.	1.0	117
33	Urological Complications in 210 Consecutive Simultaneous Pancreas-Kidney Transplants with Bladder Drainage. Annals of Surgery, 1993, 218, 561-570.	4.2	116
34	RETRANSPLANTATION OF THE LIVERâ€”A SEVEN-YEAR EXPERIENCE. Transplantation, 1993, 55, 1083-1086.	1.0	110
35	The Use of UW Solution in Clinical Transplantation A 4-year Experience. Annals of Surgery, 1992, 215, 579-585.	4.2	104
36	Underutilization of pancreas donors. Transplantation, 2003, 75, 1271-1276.	1.0	103

#	Article	IF	Citations
37	Experience With 100 Consecutive Simultaneous Kidney-Pancreas Transplants With Bladder Drainage. Annals of Surgery, 1991, 214, 703-711.	4.2	96
38	POSTTRANSPLANT INFECTION IN ENTERIC VERSUS BLADDER-DRAINED SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANT RECIPIENTS1. Transplantation, 1998, 66, 1746-1750.	1.0	96
39	Relationships between sclerosing cholangitis, inflammatory bowel disease, and cancer in patients undergoing liver transplantation. Surgery, 1995, 118, 615-620.	1.9	92
40	Donor-Directed MHC Class I Antibody Is Preferentially Cleared from Sensitized Recipients of Combined Liver/Kidney Transplants. American Journal of Transplantation, 2011, 11, 841-847.	4.7	92
41	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 631-647.	1.0	91
42	Living Related and Unrelated Donors for Kidney Transplantation A 28-Year Experience. Annals of Surgery, 1995, 222, 353-364.	4.2	91
43	Simultaneous Pancreas-Kidney Transplantation From Donation After Cardiac Death. Annals of Surgery, 2005, 242, 716-723.	4.2	89
44	BAFF Is Increased in Renal Transplant Patients Following Treatment with Alemtuzumab. American Journal of Transplantation, 2009, 9, 1835-1845.	4.7	88
45	Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis. Hepatology, 2013, 57, 708-715.	7.3	88
46	Longitudinal Studies of a B Cellâ€“Derived Signature of Tolerance in Renal Transplant Recipients. American Journal of Transplantation, 2015, 15, 2908-2920.	4.7	87
47	Campath-1H Use in Pediatric Renal Transplantation. American Journal of Transplantation, 2005, 5, 1569-1573.	4.7	85
48	Liver transplantation for HELLP syndrome. Liver Transplantation, 2005, 11, 224-228.	2.4	85
49	Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. Journal of the American Society of Nephrology: JASN, 2019, 30, 1206-1219.	6.1	85
50	T-lymphocyte Alloresponses of Campath-1H-Treated Kidney Transplant Patients. Transplantation, 2006, 81, 81-87.	1.0	83
51	Macrophages Driven to a Novel State of Activation Have Anti-Inflammatory Properties in Mice. Journal of Immunology, 2008, 180, 335-349.	0.8	80
52	HEPATIC TRANSPLANTATION INTO SENSITIZED RECIPIENTS. Transplantation, 1987, 43, 8-12.	1.0	79
53	Living unrelated renal donation: The University of Wisconsin experience. Surgery, 1998, 124, 604-611.	1.9	79
54	Noninvasive Detection of Acute and Chronic Injuries in Human Renal Transplant by Elevation of Multiple Cytokines/Chemokines in Urine. Transplantation, 2009, 87, 1814-1820.	1.0	77

#	Article	IF	Citations
55	Metastable Tolerance to Rhesus Monkey Renal Transplants Is Correlated with Allograft TGF-Î²1+CD4+T Regulatory Cell Infiltrates. Journal of Immunology, 2004, 172, 5753-5764.	0.8	76
56	Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model1. Transplantation, 2004, 77, 914-920.	1.0	74
57	Unique Aspects of Rejection and Tolerance in Liver Transplantation. Seminars in Liver Disease, 2009, 29, 091-101.	3.6	73
58	Hypoxia of the growing liver accelerates regeneration. Surgery, 2017, 161, 666-679.	1.9	73
59	A STUDY COMPARING MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN SIMULTANEOUS PANCREAS-KIDNEY TRANSPLANTATION1. Transplantation, 1998, 66, 1751-1759.	1.0	72
60	THE EFFECT OF DONOR AGE, RECIPIENT AGE, AND HLA MATCH ON IMMUNOLOGIC GRAFT SURVIVAL IN CADAVER RENAL TRANSPLANT RECIPIENTS1. Transplantation, 1992, 53, 55-58.	1.0	71
61	Infected Bilomas in Liver Transplant Recipients, Incidence, Risk Factors and Implications for Prevention. American Journal of Transplantation, 2004, 4, 574-582.	4.7	71
62	Identification of new Mamu-DRB alleles using DGGE and direct sequencing. Immunogenetics, 1997, 45, 171-179.	2.4	69
63	Peripheral vascular disease and renal transplant artery stenosis: a reappraisal of transplant renovascular disease. Clinical Transplantation, 1999, 13, 349-355.	1.6	69
64	Calcineurin Inhibitor Withdrawal After Renal Transplantation with Alemtuzumab: Clinical Outcomes and Effect on T-Regulatory Cells. American Journal of Transplantation, 2008, 8, 1529-1536.	4.7	69
65	Early and Limited Use of Tacrolimus to Avoid Rejection in an Alemtuzumab and Sirolimus Regimen for Kidney Transplantation: Clinical Results and Immune Monitoring. American Journal of Transplantation, 2009, 9, 1087-1098.	4.7	67
66	Humoral Compensation after Bortezomib Treatment of Allosensitized Recipients. Journal of the American Society of Nephrology: JASN, 2017, 28, 1991-1996.	6.1	67
67	Outcomes at 3â€ƒyears of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transplant International, 2006, 19, 885-892.	1.6	66
68	THE INFLUENCE OF NATIVE NEPHRECTOMY ON THE INCIDENCE OF RECURRENT DISEASE FOLLOWING RENAL TRANSPLANTATION FOR PRIMARY GLOMERULONEPHRITIS1. Transplantation, 1996, 61, 228-234.	1.0	66
69	ORTHOTOPIC LIVER TRANSPLANTATION IN PATIENTS 60 YEARS OF AGE AND OLDER. Transplantation, 1991, 51, 431-432.	1.0	65
70	Primate renal transplants using immunotoxin. Surgery, 1998, 124, 438-447.	1.9	65
71	Induction immunosuppression in liver transplantation: a review. Transplant International, 2013, 26, 673-683.	1.6	63
72	Donor Factors Affecting Outcome After Pancreas Transplantation. Transplantation Proceedings, 1998, 30, 276-277.	0.6	61

#	Article	IF	Citations
73	Dual targeting: Combining costimulation blockade and bortezomib to permit kidney transplantation in sensitized recipients. American Journal of Transplantation, 2019, 19, 724-736.	4.7	61
74	Developmental Exposure to Noninherited Maternal Antigens Induces CD4+T Regulatory Cells: Relevance to Mechanism of Heart Allograft Tolerance. Journal of Immunology, 2007, 179, 6749-6761.	0.8	59
75	Liver transplantation in pediatric patients: Twenty years of experience at the University of Wisconsin. Pediatric Transplantation, 2007, 11, 661-670.	1.0	59
76	Urine Osteoprotegerin and Monocyte Chemoattractant Protein-1 in Lupus Nephritis. Journal of Rheumatology, 2009, 36, 2224-2230.	2.0	59
77	Human CD4+CD25low Adaptive T Regulatory Cells Suppress Delayed-Type Hypersensitivity during Transplant Tolerance. Journal of Immunology, 2007, 178, 3983-3995.	0.8	58
78	Tolerogenic therapies in transplantation. Frontiers in Immunology, 2012, 3, 198.	4.8	58
79	Laparoscopic vs Open Right Hepatectomy: A Value-Based Analysis. Journal of the American College of Surgeons, 2014, 218, 929-939.	0.5	58
80	Urine Metabolite Profiles Predictive of Human Kidney Allograft Status. Journal of the American Society of Nephrology: JASN, 2016, 27, 626-636.	6.1	58
81	Infant pediatric liver transplantation results equal those for older pediatric patients. Journal of Pediatric Surgery, 1998, 33, 20-23.	1.6	57
82	INDUCTION OF SPECIFIC TOLERANCE BY INTRATHYMIC INJECTION OF RECIPIENT MUSCLE CELLS TRANSFECTED WITH DONOR CLASS I MAJOR HISTOCOMPATIBILITY COMPLEX. Transplantation, 1994, 57, 990-996.	1.0	56
83	OBESITY AS A RISK FACTOR FOLLOWING RENAL TRANSPLANTATION1. Transplantation, 1995, 59, 631-633.	1.0	56
84	Risk factors for renal allograft loss in patients with systemic lupus erythematosus. Kidney International, 1996, 49, 512-517.	5.2	56
85	Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model. American Journal of Transplantation, 2015, 15, 815-822.	4.7	56
86	XENOGRAFT SURVIVAL IN TWO SPECIES COMBINATIONS USING TOTAL-LYMPHOID IRRADIATION AND CYCLOSPORINE. Transplantation, 1987, 43, 173-175.	1.0	55
87	Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical livingrelated, and living-unrelated grafts1. Transplantation, 2003, 75, 1677-1682.	1.0	51
88	Hepatocellular Carcinoma Lesion Characterization: Single-Institution Clinical Performance Review of Multiphase Gadolinium-enhanced MR Imagingâ€"Comparison to Prior Same-Center Results after MR Systems Improvements. Radiology, 2011, 261, 824-833.	7.3	51
89	Racial and socioeconomic disparities in pediatric and young adult liver transplant outcomes. Liver Transplantation, 2014, 20, 100-115.	2.4	51
90	Openâ€label prospective study of the safety and efficacy of glassâ€based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer, 2015, 121, 2164-2174.	4.1	51

#	Article	IF	Citations
91	Crosstalk Between T and B Cells in the Germinal Center After Transplantation. Transplantation, 2017, 101, 704-712.	1.0	51
92	Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2019, 30, 2399-2411.	6.1	51
93	Monitoring of kidney and simultaneous pancreas-kidney transplantation rejection by release of donor-specific, soluble HLA class I. Human Immunology, 1994, 40, 191-201.	2.4	50
94	SPLIT TOLERANCE INDUCED BY IMMUNOTOXIN IN A RHESUS KIDNEY ALLOGRAFT MODEL1. Transplantation, 1997, 63, 1339-1345.	1.0	50
95	Simultaneous Pancreasâ€“Kidney (SPK) Transplantation from Controlled Non-Heart-Beating Donors (NHBDs). Cell Transplantation, 2000, 9, 889-893.	2.5	49
96	Superior Long-Term Results of Simultaneous Pancreas-Kidney Transplantation from Pediatric Donors. American Journal of Transplantation, 2004, 4, 2093-2101.	4.7	49
97	Identification of Potential Cytokine Pathways for Therapeutic Intervention in Murine Primary Biliary Cirrhosis. PLoS ONE, 2013, 8, e74225.	2.5	49
98	ANALYSIS OF PRIMATE RENAL ALLOGRAFTS AFTER T-CELL DEPLETION WITH ANTI-CD3-CRM91,2. Transplantation, 1998, 66, 5-13.	1.0	49
99	The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis. American Journal of Pathology, 2012, 181, 1693-1701.	3.8	48
100	Correlation Between Human Leukocyte Antigen Antibody Production and Serum Creatinine in Patients Receiving Sirolimus Monotherapy after Campath-1H Induction. Transplantation, 2004, 78, 919-924.	1.0	47
101	Infected Bilomas in Liver Transplant Recipients: Clinical Features, Optimal Management, and Risk Factors for Mortality. Clinical Infectious Diseases, 2004, 39, 517-525.	5.8	46
102	Alemtuzumab Induction and Antibody-Mediated Kidney Rejection After Simultaneous Pancreas-Kidney Transplantation. Transplantation, 2009, 87, 125-132.	1.0	46
103	Comparison between liver transplantation and resection for hilar cholangiocarcinoma: A systematic review and meta-analysis. PLoS ONE, 2019, 14, e0220527.	2.5	46
104	CXCR3-mediated T-cell chemotaxis involves ZAP-70 and is regulated by signalling through the T-cell receptor. Immunology, 2007, 120, 467-485.	4.4	45
105	ILIAC ARTERY PSEUDOANEURYSM FOLLOWING RENAL TRANSPLANTATION PRESENTING AS LUMBOSACRAL PLEXOPATHY. Transplantation, 1999, 67, 1077-1078.	1.0	45
106	A Comparison of Alemtuzumab with Basiliximab Induction in Simultaneous Pancreasâ€“Kidney Transplantation. American Journal of Transplantation, 2008, 8, 1702-1710.	4.7	43
107	The INTUIT Study: Investigating Neuroinflammation Underlying Postoperative Cognitive Dysfunction. Journal of the American Geriatrics Society, 2019, 67, 794-798.	2.6	43
108	Infections after the use of alemtuzumab in solid organ transplant recipients: a comparative study. Diagnostic Microbiology and Infectious Disease, 2010, 66, 7-15.	1.8	42

#	Article	IF	Citations
109	Tolerance and near-tolerance strategies in monkeys and their application to human renal transplantation. Immunological Reviews, 2001, 183, 205-213.	6.0	41
110	Present experience with Campath-1H in organ transplantation and its potential use in pediatric recipients. Pediatric Transplantation, 2004, 8, 106-112.	1.0	41
111	Anti-CD40 ligand monoclonal antibody delays the progression of murine autoimmune cholangitis. Clinical and Experimental Immunology, 2013, 174, 364-371.	2.6	41
112	Anomalous biliary ducts associated with duodenal atresia. Journal of Pediatric Surgery, 1990, 25, 1266-1269.	1.6	40
113	Textbook Outcomes in Liver Transplantation. World Journal of Surgery, 2020, 44, 3470-3477.	1.6	40
114	ADENOVIRUS-MEDIATED GENE TRANSFER INTO RAT CARDIAC ALLOGRAFTS. Transplantation, 1996, 61, 1726-1729.	1.0	40
115	Liver transplantation as definitive therapy for complications after arterial embolization for hepatic manifestations of hereditary hemorrhagic telangiectasia. Liver Transplantation, 1998, 4, 483-490.	1.8	39
116	Successful desensitization with proteasome inhibition and costimulation blockade in sensitized nonhuman primates. Blood Advances, 2017, 1, 2115-2119.	5.2	39
117	Risk factors and outcomes in post-liver transplantation bile duct stones and casts: A case-control study. Liver Transplantation, 2008, 14, 1461-1465.	2.4	38
118	SUCCESSFUL CONVERSION FROM CONVENTIONAL IMMUNOSUPPRESSION TO ANTI-CD154 MONOCLONAL ANTIBODY COSTIMULATORY MOLECULE BLOCKADE IN RHESUS RENAL ALLOGRAFT RECIPIENTS1,2. Transplantation, 2001, 72, 587-597.	1.0	38
119	Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection1. Transplantation, 2003, 76, 524-530.	1.0	37
120	Overcoming Chronic Rejectionâ€”Can it B?. Transplantation, 2009, 88, 955-961.	1.0	37
121	Antibody-Mediated Rejection in Sensitized Nonhuman Primates: Modeling Human Biology. American Journal of Transplantation, 2016, 16, 1726-1738.	4.7	37
122	Identification of bacterial antigens in circulating immune complexes of infective endocarditis.. Journal of Clinical Investigation, 1982, 70, 271-280.	8.2	37
123	Knowledge about transplantation tolerance gained in primates. Current Opinion in Immunology, 2000, 12, 552-556.	5.5	36
124	Improvement in Liver Transplant Outcomes From Older Donors. Annals of Surgery, 2019, 270, 333-339.	4.2	36
125	The past, present, and future of costimulation blockade in organ transplantation. Current Opinion in Organ Transplantation, 2019, 24, 391-401.	1.6	36
126	B cells in transplant tolerance and rejection: friends or foes?. Transplant International, 2020, 33, 30-40.	1.6	36

#	Article	IF	Citations
127	100 Consecutive liver transplants in infants and children: An 8-year experience. Journal of Pediatric Surgery, 1994, 29, 1135-1140.	1.6	35
128	Strategies for tolerance induction in nonhuman primates. Current Opinion in Immunology, 1998, 10, 513-517.	5.5	35
129	Alemtuzumab Induction and Recurrence of Glomerular Disease After Kidney Transplantation. Transplantation, 2007, 83, 1429-1434.	1.0	35
130	The role of B cells in solid organ transplantation. Seminars in Immunology, 2012, 24, 96-108.	5.6	35
131	Urine proteomics in kidney transplantation. Transplantation Reviews, 2014, 28, 15-20.	2.9	35
132	THE IMPACT OF HYPOALBUMINEMIA IN KIDNEY-PANCREAS TRANSPLANT RECIPIENTS1. Transplantation, 1999, 68, 72-75.	1.0	35
133	Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Transplant International, 2008, 21, 625-636.	1.6	34
134	Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. Pediatric Transplantation, 2008, 12, 447-455.	1.0	34
135	Unaltered Graft Survival and Intragraft Lymphocytes Infiltration in the Cardiac Allograft of Cxcr3âˆ’/âˆ’ Mouse Recipients. American Journal of Transplantation, 2008, 8, 1593-1603.	4.7	34
136	Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. Hepatology, 2012, 56, 2071-2081.	7.3	34
137	One Size Does Not Fit Allâ€”Regional Variation in the Impact of the Share 35 Liver Allocation Policy. American Journal of Transplantation, 2016, 16, 137-142.	4.7	34
138	PROCUREMENT, PRESERVATION, AND TRANSPORT OF CADAVER KIDNEYS. Surgical Clinics of North America, 1998, 78, 41-54.	1.5	33
139	Surveillance of Acute Rejection in Baboon Renal Transplantation by Elevation of Interferon-Î³ Inducible Protein-10 and Monokine Induced by Interferon-Î³ in Urine. Transplantation, 2004, 78, 1002-1007.	1.0	33
140	Nonhuman Primate Infections after Organ Transplantation. ILAR Journal, 2008, 49, 209-219.	1.8	33
141	Treatment with immunotoxin. Philosophical Transactions of the Royal Society B: Biological Sciences, 2001, 356, 681-689.	4.0	32
142	CD28 Ligation Induces Tyrosine Phosphorylation of Pyk2 but Not Fak in Jurkat T Cells. Journal of Biological Chemistry, 1999, 274, 6735-6740.	3.4	31
143	The Impact of Donor Variables on the Outcome of Orthotopic Liver Transplantation for Hepatitis C. Transplantation Proceedings, 2008, 40, 219-223.	0.6	31
144	The Association Between Hospital Finances and Complications After Complex Abdominal Surgery. Annals of Surgery, 2015, 262, 273-279.	4.2	31

#	Article	IF	Citations
145	Metastable tolerance in nonhuman primates and humans. Transplantation, 2004, 77, 936-939.	1.0	30
146	Patterns ofDe NovoAllo B Cells and Antibody Formation in Chronic Cardiac Allograft Rejection After Alemtuzumab Treatment. American Journal of Transplantation, 2012, 12, 2641-2651.	4.7	29
147	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	12.8	29
148	Surgical portosystemic shunts for treatment of portal hypertensive bleeding: Outcome and effect on liver function. Surgery, 1999, 126, 708-713.	1.9	28
149	Utilization of pediatric donors for pancreas transplantation. Transplantation Proceedings, 1999, 31, 610-611.	0.6	28
150	Antibody-Mediated Rejection of the Kidney after Simultaneous Pancreas-Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2008, 19, 812-824.	6.1	28
151	Analysis of tumor characteristics and survival in liver transplant recipients with incidentally diagnosed hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 2001, 5, 594-602.	1.7	27
152	Domino Liver Transplantation in Maple Syrup Urine Disease: A Case Report and Review of the Literature. Transplantation Proceedings, 2013, 45, 806-809.	0.6	27
153	Improved contemporary outcomes of liver transplantation for pediatric hepatoblastoma and hepatocellular carcinoma. Pediatric Transplantation, 2018, 22, e13305.	1.0	27
154	Translational impact of NIH-funded nonhuman primate research in transplantation. Science Translational Medicine, 2019, 11, .	12.4	27
155	Preoperative carfilzomib and lulizumab based desensitization prolongs graft survival in a sensitized non-human primate model. Kidney International, 2021, 99, 161-172.	5.2	27
156	INFILTRATING CELL PHENOTYPES AND PATTERNS ASSOCIATED WITH HEPATIC ALLOGRAFT REJECTION OR ACCEPTANCE. Transplantation, 1987, 43, 169-172.	1.0	26
157	Biologics in organ transplantation. Transplant International, 2012, 25, 707-719.	1.6	26
158	IMMUNOSUPPRESSIVE EFFECTS OF AN HLA CLASS I-DERIVED PEPTIDE IN A RAT CARDIAC ALLOGRAFT MODEL. Transplantation, 1996, 61, 1222-1228.	1.0	26
159	CD28 ligation induces rapid tyrosine phosphorylation of the linker molecule LAT in the absence of Syk and ZAP-70 tyrosine phosphorylation. European Journal of Immunology, 1999, 29, 2354-2359.	2.9	25
160	Percutaneous Management of Benign Biliary Strictures with Large-Bore Catheters: Comparison between Patients with and without Orthotopic Liver Transplantation. Journal of Vascular and Interventional Radiology, 2016, 27, 219-225.e1.	0.5	25
161	A Controlled, Double-Blind, Randomized Trial of Verapamil and Cyclosporine in Cadaver Renal Transplant Patients. American Journal of Kidney Diseases, 1993, 21, 189-195.	1.9	24
162	Enhanced De Novo Alloantibody and Antibody-Mediated Injury in Rhesus Macaques. American Journal of Transplantation, 2012, 12, 2395-2405.	4.7	24

#	Article	IF	Citations
163	Lymphodepletional Strategies in Transplantation. Cold Spring Harbor Perspectives in Medicine, 2013, 3, a015511-a015511.	6.2	24
164	Evaluation of clinical outcomes of prophylactic versus preemptive cytomegalovirus strategy in liver transplant recipients. Transplant International, 2013, 26, 592-600.	1.6	24
165	Enteric Conversion of Bladder-Drained Pancreas Allografts: Experience in 95 Patients. Transplantation Proceedings, 1998, 30, 441-442.	0.6	23
166	Contemporary Strategies and Barriers to Transplantation Tolerance. Transplantation, 2018, 102, 1213-1222.	1.0	23
167	CLINICAL HEPATITIS AFTER TRANSPLANTATION OF HEPATITIS C VIRUS-POSITIVE KIDNEYS. Transplantation, 1996, 62, 1758-1762.	1.0	23
168	THE INFLUENCE OF RS-61443 ON ANTIBODY-MEDIATED REJECTION. Transplantation, 1992, 53, 696.	1.0	22
169	Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. Journal of Surgical Oncology, 2014, 109, 533-541.	1.7	22
170	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant International, 1997, 10, 152-156.	1.6	20
171	Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. Human Immunology, 1998, 59, 415-425.	2.4	20
172	Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes. Transplantation Direct, 2018, 4, e349.	1.6	20
173	Gene therapy in transplantation. Transplant Immunology, 1996, 4, 257-264.	1.2	19
174	Ureteroneocystostomy for renal transplantation. Journal of the American College of Surgeons, 1999, 188, 707-709.	0.5	19
175	Proceed with Caution: Liver Transplantation for Metastatic Neuroendocrine Tumors. Annals of Surgery, 1997, 225, 345-346.	4.2	19
176	Altered Distribution of H60 Minor H Antigen-Specific CD8 T Cells and Attenuated Chronic Vasculopathy in Minor Histocompatibility Antigen Mismatched Heart Transplantation in Cxcr3â^'/â^' Mouse Recipients. Journal of Immunology, 2007, 179, 8016-8025.	0.8	18
177	Transient CD86 Expression on Hepatitis C Virus-Specific CD8+ T Cells in Acute Infection Is Linked to Sufficient IL-2 Signaling. Journal of Immunology, 2010, 184, 2410-2422.	0.8	18
178	Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. American Journal of Transplantation, 2016, 16, 2612-2623.	4.7	18
179	The Volume-outcome Relationship in Deceased Donor Kidney Transplantation and Implications for Regionalization. Annals of Surgery, 2018, 267, 1169-1172.	4.2	18
180	Primary Vascularization of the Graft Determines the Immunodominance of Murine Minor H Antigens during Organ Transplantation. Journal of Immunology, 2011, 187, 3997-4006.	0.8	17

#	Article	IF	Citations
181	Determination of the Functional Status of Alloreactive T Cells by Interferon-?? Kinetics. Transplantation, 2006, 81, 590-598.	1.0	16
182	The Effectiveness of Locoregional Therapies versus Supportive Care in Maintaining Survival within the Milan Criteria in Patients with Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology, 2010, 21, 1197-1204.	0.5	16
183	Miles to Goâ€¦. American Journal of Transplantation, 2011, 11, 1119-1120.	4.7	16
184	Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization. Frontiers in Immunology, 2021, 12, 694763.	4.8	16
185	The influence of dose and dose rate of total lymphoid irradiation in the rat cardiac allograft model. Radiotherapy and Oncology, 1987, 9, 311-318.	0.6	15
186	Regulation of T Cell Receptor- and CD28-induced Tyrosine Phosphorylation of the Focal Adhesion Tyrosine Kinases Pyk2 and Fak by Protein Kinase C. Journal of Biological Chemistry, 2000, 275, 1344-1350.	3.4	14
187	Selenium-Binding Protein-1 in Smooth Muscle Cells is Downregulated in a Rhesus Monkey Model of Chronic Allograft Nephropathy. American Journal of Transplantation, 2005, 5, 58-67.	4.7	14
188	Development of tolerogenic strategies in the clinic. Philosophical Transactions of the Royal Society B: Biological Sciences, 2005, 360, 1739-1746.	4.0	14
189	Thrombalexin: Use of a Cytotopic Anticoagulant to Reduce Thrombotic Microangiopathy in a Highly Sensitized Model of Kidney Transplantation. American Journal of Transplantation, 2017, 17, 2055-2064.	4.7	14
190	MULTIVARIATE ANALYSIS OF DONOR-SPECIFIC VERSUS RANDOM TRANSFUSION PROTOCOLS IN HAPLOIDENTICAL LIVING-RELATED TRANSPLANTS. Transplantation, 1991, 51, 382-384.	1.0	13
191	Potentiation of CD3-induced expression of the linker for activation of T cells (LAT) by the calcineurin inhibitors cyclosporin A and FK506. Blood, 2000, 95, 2733-2741.	1.4	13
192	Effect of immunosuppressants on T-cell subsets observed in vivo using carboxy-fluorescein diacetate succinimidyl ester labeling1. Transplantation, 2003, 75, 1075-1077.	1.0	13
193	Impact of Leukocyte Function-Associated Antigen-1 Blockade on Endogenous Allospecific T Cells to Multiple Minor Histocompatibility Antigen Mismatched Cardiac Allograft. Transplantation, 2015, 99, 2485-2493.	1.0	13
194	Expanding the Donor Pool With Normothermic Ex Vivo Liver Perfusion: The Future Is Now. American Journal of Transplantation, 2016, 16, 3075-3076.	4.7	13
195	Bridging Locoregional Therapy Prolongs Survival in Patients Listed for Liver Transplant with Hepatocellular Carcinoma. CardioVascular and Interventional Radiology, 2017, 40, 410-420.	2.0	13
196	Piceatannol in combination with low doses of cyclosporine a prolongs kidney allograft survival in a stringent rat transplantation model1,2. Transplantation, 2002, 74, 1609-1617.	1.0	12
197	Immunoregulation and Tolerance. Transplantation Proceedings, 2010, 42, S13-S15.	0.6	12
198	Innate networking: Thrombotic microangiopathy, the activation of coagulation and complement in the sensitized kidney transplant recipient. Transplantation Reviews, 2018, 32, 119-126.	2.9	12

#	Article	IF	Citations
199	Experimental modeling of desensitization: What have we learned about preventing AMR?. American Journal of Transplantation, 2020, 20, 2-11.	4.7	12
200	Definition and Analysis of Textbook Outcome: A Novel Quality Measure in Kidney Transplantation. World Journal of Surgery, 2021, 45, 1504-1513.	1.6	12
201	Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. International Journal of Radiation Oncology Biology Physics, 1996, 34, 1055-1059.	0.8	11
202	Two distinct forms of soluble MHC class I molecules synthesized by different mechanisms in normal rat cells in vitro. Human Immunology, 1998, 59, 404-414.	2.4	11
203	An overview of the actions of cyclosporine and FK506. Transplantation Reviews, 2003, 17, 165-171.	2.9	11
204	Interleukin-15 Receptor Blockade in Non-Human Primate Kidney Transplantation. Transplantation, 2010, 89, 937-944.	1.0	11
205	Belatacept: Is There BENEFIT for Liver Transplantation Too?. American Journal of Transplantation, 2014, 14, 1717-1718.	4.7	11
206	ACTIVATION OF T LYMPHOCYTES FOR ADHESION AND CYTOKINE EXPRESSION BY TOXIN-CONJUGATED ANTI-CD3 MONOCLONAL ANTIBODIES1. Transplantation, 1999, 68, 693-698.	1.0	11
207	PRETRANSPLANT STATUS AND PATIENT SURVIVAL FOLLOWING LIVER TRANSPLANTATION. Transplantation, 1995, 60, 920-925.	1.0	10
208	CD40:CD154 interactions and allograft rejection. Current Opinion in Organ Transplantation, 2000, 5, 10-15.	1.6	10
209	Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells. International Immunology, 2003, 15, 1369-1378.	4.0	10
210	A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?. Transplantation, 2019, 103, 1675-1682.	1.0	10
211	Transplant research in nonhuman primates to evaluate clinically relevant immune strategies in organ transplantation. Transplantation Reviews, 2019, 33, 115-129.	2.9	10
212	INCREASED GLOMERULAR DEPOSITS OF VON WILLEBRAND FACTOR IN CHRONIC, BUT NOT ACUTE, REJECTION OF PRIMATE RENAL ALLOGRAFTS1. Transplantation, 2000, 70, 877-886.	1.0	10
213	Infiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence. Transplantation Direct, 2017, 3, e206.	1.6	9
214	Improved survival in simultaneous lung-liver recipients and candidates in the modern era of lung allocation. Journal of Surgical Research, 2018, 231, 395-402.	1.6	9
215	Donor apoptotic cellâ€“based therapy for effective inhibition of donor-specific memory T and B cells to promote long-term allograft survival in allosensitized recipients. American Journal of Transplantation, 2020, 20, 2728-2739.	4.7	9
216	GRAFT SURVIVAL IN A RHESUS RENAL TRANSPLANT MODEL AFTER IMMUNOTOXIN-MEDIATED T-CELL DEPLETION IS ENHANCED BY MYCOPHENOLATE AND STEROIDS1,2. Transplantation, 2001, 72, 581-587.	1.0	9

#	Article	IF	Citations
217	Single-center experience with renal transplantation in patients with Wegener's granulomatosis. Transplant International, 1997, 10, 152-156.	1.6	8
218	Post-transplant lymphoproliferative disorder associated with immunosuppressive therapy for renal transplantation in rhesus macaques (Macaca mulatta). Experimental and Toxicologic Pathology, 2013, 65, 1019-1024.	2.1	8
219	Equalizing MELD Scores Over Broad Geographies Is Not the Most Efficacious Way to Allocate a Scarce Resource in a Value-based Environment. Annals of Surgery, 2015, 262, 220-223.	4.2	8
220	Use of Donor Serum to Prevent Passive Transfer of Hyperacute Rejection. Journal of Surgical Research, 1994, 57, 150-155.	1.6	7
221	Reversal of acute allograft rejection using immunotoxin. Transplantation Proceedings, 1998, 30, 2150-2151.	0.6	7
222	T-cell depletion as a means of achieving tolerance. Current Opinion in Organ Transplantation, 2000, 5, 96-102.	1.6	7
223	IL-21 Biased Alemtuzumab Induced Chronic Antibody-Mediated Rejection Is Reversed by LFA-1 Costimulation Blockade. Frontiers in Immunology, 2018, 9, 2323.	4.8	7
224	Pointâ€ofâ€Care Assessment of DCD Livers During Normothermic Machine Perfusion in a Nonhuman Primate Model. Hepatology Communications, 2021, 5, 1527-1542.	4.3	7
225	Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model. Frontiers in Immunology, 2021, 12, 660900.	4.8	7
226	The Effect of TLI and Cyclosporine on Xenograft Survival. Transplantation, 1990, 50, 1082.	1.0	6
227	Human interleubâ€2 and lymphoproliferative (Tâ€helper cell) responses to soluble HLA class I antigens in vitro: I. Specificity for polymorphic domains^{1,2}. Tissue Antigens, 1993, 42, 35-38.	1.0	6
228	Impact of improving immunosuppressive treatment on outcome in cadaveric kidney transplantation. Surgery, 1996, 120, 719-724.	1.9	6
229	Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. Transplant Immunology, 1998, 6, 169-175.	1.2	6
230	Immunologic Risks of Combined Kidneyâ€“Pancreas Transplantation. Transplantation Proceedings, 1998, 30, 249-250.	0.6	6
231	From Eck's Fistula to TIPS. Annals of Surgery, 2003, 238, S49-S55.	4.2	6
232	Systems biological analyses reveal the hepatitis C virus (HCV)â€specific regulation of hematopoietic development. Hepatology, 2015, 61, 843-856.	7.3	6
233	Identification and Management of Abdominal Wall Varices in Pregnancy. Obstetrics and Gynecology, 2018, 132, 882-887.	2.4	6
234	The impact of human leukocyte antigen donor and recipient serotyping and matching on liver transplant graft failure in primary sclerosing cholangitis, autoimmune hepatitis, and primary biliary cholangitis. Clinical Transplantation, 2018, 32, e13388.	1.6	6

#	Article	IF	Citations
235	IMMUNOTOXIN FN18-CRM9 INDUCES STRONGER T CELL SIGNALING THAN UNCONJUGATED MONOCLONAL ANTIBODY FN1812. Transplantation, 2001, 72, 496-503.	1.0	6
236	A cell-based multiplex immunoassay platform using fluorescent protein-barcoded reporter cell lines. Communications Biology, 2021, 4, 1338.	4.4	6
237	Irradiation for xenogeneic transplantation. Radiotherapy and Oncology, 1990, 18, 29-37.	0.6	5
238	Clinical trials: where are we now?. Immunological Reviews, 2003, 196, 237-246.	6.0	5
239	Elevation of multiple cytokines/chemokines in urine of human renal transplant recipients with acute and chronic injuries: potential usage for diagnosis and monitoring. Transplantation Reviews, 2006, 20, 165-171.	2.9	5
240	Outcomes in Kidney Transplantation Between Veterans Affairs and Civilian Hospitals. Annals of Surgery, 2020, 272, 506-510.	4.2	5
241	Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient. Journal of Clinical Medicine, 2021, 10, 3656.	2.4	5
242	Prevention trumps treatment of antibody-mediated transplant rejection. Journal of Clinical Investigation, 2010, 120, 1036-1039.	8.2	5
243	Introducing thymus for promoting transplantation tolerance. Journal of Allergy and Clinical Immunology, 2022, 150, 549-556.	2.9	5
244	Harnessing the B Cell Response in Kidney Transplantation â€“ Current State and Future Directions. Frontiers in Immunology, 0, 13, .	4.8	5
245	Seek and You Will Find: Antibody and the Liver. American Journal of Transplantation, 2011, 11, 424-425.	4.7	4
246	Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation. Frontiers in Immunology, 2017, 8, 1615.	4.8	4
247	Allo-Specific Humoral Responses: New Methods for Screening Donor-Specific Antibody and Characterization of HLA-Specific Memory B Cells. Frontiers in Immunology, 2021, 12, 705140.	4.8	4
248	Optical coherence tomography of small intestine allograft biopsies using a handheld surgical probe. Journal of Biomedical Optics, 2021, 26, .	2.6	4
249	Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes. Transplantation Proceedings, 1999, 31, 785.	0.6	3
250	Prolongation of Long-Term Kidney Graft Survival by a Simultaneous Liver Transplant: The Liver Does It, and the Heart Does It Too.. Transplantation, 2002, 74, 1370-1371.	1.0	3
251	Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. Transplant Immunology, 2004, 13, 147-154.	1.2	3
252	Hepatic steatosis and liver transplantation. Current Opinion in Organ Transplantation, 2004, 9, 123-129.	1.6	3

#	Article	IF	Citations
253	Review: chemokines in transplantation. Transplantation Reviews, 2007, 21, 107-118.	2.9	3
254	HLA-C and Liver Transplant Outcomes: Interpreting the Facts. American Journal of Transplantation, 2009, 9, 1491-1492.	4.7	3
255	Guidance for Liver Transplant Immunosuppression. American Journal of Transplantation, 2011, 11, 886-887.	4.7	3
256	Surgical Technique in Transplantation: How Much Does It Matter?. American Journal of Transplantation, 2015, 15, 2791-2792.	4.7	3
257	ANALYSIS OF REJECTION AND ATN AFTER INDUCTION WITH ATG, BASILIXIMAB AND DACLIZIMAB IN CADAVERIC KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, S546.	1.0	3
258	Novel agents or strategies for immunosuppression after renal transplantation. Current Opinion in Organ Transplantation, 2003, 8, 172-178.	1.6	2
259	Challenging Choices. Annals of Surgery, 2004, 239, 160-161.	4.2	2
260	Surgical invention and commercialization. Surgery, 2008, 143, 175-181.	1.9	2
261	Regulating T Cell Behavior. American Journal of Transplantation, 2016, 16, 1949-1950.	4.7	2
262	Results of Renal Transplantation. , 2019, , 684-708.		2
263	Percutaneous Splenorenal Shunt Creation in a Patient with Chronic Portomesenteric Thrombosis. Journal of Vascular and Interventional Radiology, 2020, 31, 1408-1409.	0.5	2
264	Pharmacological approaches to antibody-mediated rejectionâ€"Are we getting closer?. American Journal of Transplantation, 2020, 20, 2637-2638.	4.7	2
265	Early Course of the Patient with a Kidney Transplant. , 2008, , 210-219.		2
266	Results of Renal Transplantation. , 2008, , 657-675.		2
267	DETECTION OF CELLS RECOGNIZING DONOR GRAFTDERIVED FIBROBLASTS IN THE BLOOD OF ALLOGRAFTREJECTING ANIMALS.. Transplantation, 2000, 69, S152.	1.0	1
268	IMMUNOREGULATION IN MONKEY KIDNEY ALLOGRAFT ACCEPTANCE: BYSTANDER SUPPRESSION OF DTH TRIGGERED BY DONOR ANTIGENS.. Transplantation, 2000, 69, S242.	1.0	1
269	Steps toward transplantation tolerance in the clinic. Transplantation Proceedings, 2001, 33, 3844-3845.	0.6	1
270	Whatâ€™s new in transplantation. Journal of the American College of Surgeons, 2001, 192, 366-371.	0.5	1

#	Article	IF	Citations
271	How does alemtuzumab affect long-term graft and patient outcomes after deceased-donor kidney transplantation?. Nature Clinical Practice Nephrology, 2005, 1, 74-75.	2.0	1
272	Immunosuppression in nonhuman primates. Transplantation Reviews, 2006, 20, 131-138.	2.9	1
273	Elevated HbA1c in donor organs from patients without a diagnosis of diabetes portends worse liver allograft survival. Clinical Transplantation, 2017, 31, e13047.	1.6	1
274	Early Course of the Patient With a Kidney Transplant. , 2019, , 198-211.		1
275	Humoral Immunity Induced By Viral Infection Provides a Major Barrier To Hematopoietic Cell Transplantation. Blood, 2013, 122, 894-894.	1.4	1
276	Results of Renal Transplantation. , 2014, , 676-697.		1
277	Parallels between antibody-mediated rejection and ischemic kidney injury with respect to B cell activation. Annals of Translational Medicine, 2019, 7, S151-S151.	1.7	1
278	Antibody-Mediated Graft Rejection in Nonhuman Primate Models: Comparison of Sensitized Allotransplant and Xenotransplant Rejection. , 2020, , 157-164.		1
279	A Historical Cohort in Kidney Transplantation: 55-Year Follow-Up of 72 HLA-Identical, Donor-Recipient Pairs. Journal of Clinical Medicine, 2021, 10, 5505.	2.4	1
280	Long-term outcomes in simultaneous pancreas-kidney transplantation: lessons relearned. Clinical Transplants, 2003, , 215-20.	0.2	1
281	Letter to the editor in response to: Measuring success in pig to non-human-primate renal xenotransplantation: Systematic review and comparative outcomes analysis of 1051 life sustaining NHP renal allo- and xeno-transplants by Firl and Markmann. American Journal of Transplantation, 2022, 22, 1933-1934.	4.7	1
282	Immunotoxins in organ transplantation. Current Opinion in Organ Transplantation, 1997, 2, 97.	1.6	0
283	Emergency Portacaval Shunts: Is Orloff Correct?. HPB Surgery, 1997, 10, 253-265.	2.2	0
284	EARLY RESULTS IN THE USE OF THYMOGLOBULIN AND SIMULECT AS INDUCTION THERAPY IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS.. Transplantation, 2000, 69, S160.	1.0	0
285	Alemtuzumab and tolerance: the university of wisconsin experience. Transplantation Reviews, 2003, 17, S26-S28.	2.9	0
286	Involvement of linker for activation of T cells in the costimulatory signaling pathways. Transplantation Proceedings, 2003, 35, 553-554.	0.6	0
287	Mycophenolate mofetil: what is the evidence that it decreases chronic rejection?. Current Opinion in Organ Transplantation, 2003, 8, 313-316.	1.6	0
288	Incidental living donor nephrectomy: a unique expansion of the donor pool. Nephrology Dialysis Transplantation, 2005, 20, 245-246.	0.7	0

#	Article	IF	Citations
289	Liver transplantation 2007: where do we go from here?. Current Opinion in Organ Transplantation, 2007, 12, 211-214.	1.6	0
290	Cytokine kinetics profiling in pediatric renal transplant recipients. Pediatric Transplantation, 2010, 14, 636-645.	1.0	0
291	Reply to VanhoveetÂal. Transplant International, 2013, 26, e26-e27.	1.6	0
292	Starting Well: Induction Immunosuppression after Organ Transplantation. Transplant International, 2013, 26, 661-661.	1.6	0
293	An Introduction to Pediatric Organ Transplantation. , 2014, , 1353-1356.		0
294	Transplant Clinic Management. , 2014, , 1518-1532.		0
295	Abdominal Solid Organ Transplantation Fellowship Training. , 2014, , 1562-1565.		0
296	Medical Solid Organ Transplant Fellowship Training. , 2014, , 1566-1571.		0
297	Administration of Organ Procurement and Allocation. , 2014, , 251-263.		0
298	Reply to: "Percutaneous Management of Benign Biliary Strictures: Is It Time to Focus on Reducing Procedure Invasiveness?". Journal of Vascular and Interventional Radiology, 2016, 27, 936-937.	0.5	0
299	Portal hypertensive bleeding. , 2017, , 1218-1230.e3.		0
300	Toward Long-term Livers. Annals of Surgery, 2019, 269, 28-29.	4.2	0
301	Targeting Calcium Releaseâ€“activated Calcium Channel Is Not Sufficient to Prevent Rejection in Nonhuman Primate Kidney Transplantation. Transplantation, 2020, 104, 970-980.	1.0	0
302	Kidney Transplantation and Dialysis Access. , 2001, , 1449-1462.		0
303	Costimulatory Blockade as a Therapeutic Regimen for Prolonging Allograft Survival and Inducing Tolerance: An Overview of Recent Research. , 2001, , 127-158.		0
304	Tolerance induction. , 2001, , 149-168.		0
305	Vascular Access for Dialysis, Chemotherapy, and Nutritional Support. , 2008, , 1457-1468.		0
306	Location of portosystemic shunting. , 2012, , 1146-1158.e3.		0

#	Article	IF	Citations
307	Preface to the Seventh Edition. , 2014, , xi.		0
308	Early Course of the Patient withÂaÂKidney Transplant. , 2014, , 204-215.		0
309	Transjugular Intrahepatic Portosystemic Shunt for a Challenging Pregnancy. American Journal of Gastroenterology, 2020, 115, 1935-1935.	0.4	0
310	Kidney Transplantation and Dialysis Access. , 2003, , 607-615.		0
311	Another Step Toward Becoming a Transplant Community. Annals of Surgery, 2021, 273, e149-e150.	4.2	0